ARTICLE | Clinical News

Olmutinib: Additional Phase I/II data

June 27, 2016 7:00 AM UTC

Additional data from 70 evaluable patients with T790M EGFR mutation-positive NSCLC who developed resistance to previous EGFR TKIs in the open-label, South Korean Phase I/II HM-EMSI-101 trial showed that once-daily 800 mg oral olmutinib led to an ORR of 61%, including 38 confirmed partial responses and 5 unconfirmed partial responses, plus 20 cases of stable disease. Median duration of response was 8.3 months. Median PFS was 6.9 months in all patients, 8.8 months in patients who received 1 prior systemic treatment (n=19) and 6.8 months in patients who received >=2 prior treatments (n=57). Data were presented at the American Society of Clinical Oncology meeting in Chicago. Data were previously reported from the trial (see BioCentury, June 15, 2015 & Jan. 4, 2016). ...